{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Samarium+153", "query": { "intervention": "Samarium 153" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 17, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Samarium+153&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-11T17:31:54.231Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00478075", "title": "Samarium Sm 153 Lexidronam Pentasodium and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma and Plasma Cell Neoplasm" ], "interventions": [ { "name": "bortezomib", "type": "DRUG" }, { "name": "immunologic technique", "type": "OTHER" }, { "name": "samarium Sm 153 lexidronam pentasodium", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "OTHER", "RADIATION" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2005-09", "completion_date": "2009-06", "has_results": false, "last_update_posted_date": "2011-05-11", "last_synced_at": "2026-09-11T17:31:54.231Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00478075" }, { "nct_id": "NCT00551525", "title": "Samarium Sm 153 Lexidronam Pentasodium and 3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Rising Prostate-Specific Antigen Levels After Radical Prostatectomy for Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Radiotherapy", "type": "RADIATION" }, { "name": "Samarium 153", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "Radiation Therapy Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "MALE", "summary": "18 Years to 120 Years · Male only" }, "enrollment_count": 67, "start_date": "2008-04", "completion_date": "2016-12", "has_results": true, "last_update_posted_date": "2017-07-25", "last_synced_at": "2026-09-11T17:31:54.231Z", "location_count": 29, "location_summary": "Phoenix, Arizona • Auburn, California • Cameron Park, California + 22 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Auburn", "state": "California" }, { "city": "Cameron Park", "state": "California" }, { "city": "Carmichael", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00551525" }, { "nct_id": "NCT07197645", "title": "Samarium Optimized for Long-lasting Analgesia in Cancerous End-stage Bone Pain", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Bone Pain", "Metastatic Bone Tumor", "Bone Metastases in Subjects With Advanced Cancer" ], "interventions": [ { "name": "153Sm-DOTMP", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Telix Pharmaceuticals (Innovations) Pty Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2025-10-21", "completion_date": "2027-07-05", "has_results": false, "last_update_posted_date": "2026-05-14", "last_synced_at": "2026-09-11T17:31:54.231Z", "location_count": 6, "location_summary": "Miami, Florida • Houston, Texas", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07197645" }, { "nct_id": "NCT06008483", "title": "A Dose Finding Study to Treat Bone Tumor(s)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Bone Cancer", "Bone Tumor", "Solid Tumor", "Metastatic Cancer to the Bone", "Metastatic Tumor to the Bone" ], "interventions": [ { "name": "153-Sm-DOTMP (Samarium-153-DOTMP)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "QSAM Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "15 Years to 75 Years" }, "enrollment_count": 5, "start_date": "2022-04-05", "completion_date": "2024-08-08", "has_results": false, "last_update_posted_date": "2026-07-23", "last_synced_at": "2026-09-11T17:31:54.231Z", "location_count": 4, "location_summary": "Chicago, Illinois • Columbia, Missouri • New Brunswick, New Jersey + 1 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Columbia", "state": "Missouri" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06008483" }, { "nct_id": "NCT00482378", "title": "Samarium Sm 153 Lexidronam Pentasodium Combined With Zoledronic Acid or Pamidronate in Treating Patients With Relapsed or Refractory Multiple Myeloma and Bone Pain", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma and Plasma Cell Neoplasm", "Pain" ], "interventions": [ { "name": "Pamidronate", "type": "DRUG" }, { "name": "Zoledronic acid", "type": "DRUG" }, { "name": "Sm 153 lexidronam", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 39, "start_date": "2005-03-21", "completion_date": "2008-12-02", "has_results": false, "last_update_posted_date": "2018-08-14", "last_synced_at": "2026-09-11T17:31:54.231Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00482378" }, { "nct_id": "NCT00450619", "title": "153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Samarium Sm 153 lexidronam pentasodium", "type": "RADIATION" }, { "name": "Sargramostim", "type": "BIOLOGICAL" }, { "name": "Recombinant vaccinia-TRICOM vaccine", "type": "BIOLOGICAL" }, { "name": "Recombinant fowlpox-TRICOM vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "RADIATION", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 44, "start_date": "2007-02", "completion_date": "2012-11", "has_results": true, "last_update_posted_date": "2017-01-04", "last_synced_at": "2026-09-11T17:31:54.231Z", "location_count": 3, "location_summary": "Chicago, Illinois • Bethesda, Maryland • New Brunswick, New Jersey", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00450619" }, { "nct_id": "NCT00003086", "title": "Repeated Bone Marrow Transplantation in Treating Women With Advanced Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "CAF regimen", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "thiotepa", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "samarium Sm 153 lexidronam pentasodium", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Louisiana State University Health Sciences Center Shreveport", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "65 Years", "sex": "FEMALE", "summary": "21 Years to 65 Years · Female only" }, "enrollment_count": 12, "start_date": "1997-03", "completion_date": "2001-01-28", "has_results": false, "last_update_posted_date": "2020-07-14", "last_synced_at": "2026-09-11T17:31:54.231Z", "location_count": 1, "location_summary": "Shreveport, Louisiana", "locations": [ { "city": "Shreveport", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003086" }, { "nct_id": "NCT00365105", "title": "Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer", "Lung Cancer", "Metastatic Cancer", "Pain", "Prostate Cancer" ], "interventions": [ { "name": "Calcium", "type": "DIETARY_SUPPLEMENT" }, { "name": "Vitamin D", "type": "DIETARY_SUPPLEMENT" }, { "name": "zoledronic acid", "type": "DRUG" }, { "name": "Sm-153", "type": "DRUG" }, { "name": "Sr-89", "type": "RADIATION" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "DRUG", "RADIATION" ], "sponsor": "Radiation Therapy Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 261, "start_date": "2006-07-11", "completion_date": "2017-02-27", "has_results": true, "last_update_posted_date": "2024-09-20", "last_synced_at": "2026-09-11T17:31:54.231Z", "location_count": 147, "location_summary": "Mobile, Alabama • Burbank, California • Carmichael, California + 116 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Burbank", "state": "California" }, { "city": "Carmichael", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Pomona", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00365105" }, { "nct_id": "NCT00121095", "title": "Study of Samarium Sm-153 Lexidronam Combined With Docetaxel for Patients With Prostate Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Prostatic Neoplasms" ], "interventions": [ { "name": "Samarium Sm-153 lexidronam + Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cytogen Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "MALE", "summary": "Male only" }, "enrollment_count": 69, "start_date": "2005-07", "completion_date": "2008-06", "has_results": false, "last_update_posted_date": "2007-12-21", "last_synced_at": "2026-09-11T17:31:54.231Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00121095" }, { "nct_id": "NCT00559429", "title": "Study of Docetaxel +153 Sm-EDTMP in Patients With Hormone-Refractory Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "MALE", "summary": "18 Years to 80 Years · Male only" }, "enrollment_count": 13, "start_date": "2004-12", "completion_date": "2008-10", "has_results": false, "last_update_posted_date": "2008-12-17", "last_synced_at": "2026-09-11T17:31:54.231Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00559429" } ] }